Mindfulness for at Risk Youth: Understanding Substance Use and Important Mechanisms of Change

September 27, 2021 updated by: Jordan Davis, University of Southern California

This study will be the first to explore mindfulness as a prevention intervention among transition age youth and those with previous involvement in the juvenile or criminal justice system with substance use problems and history of exposure to violence/trauma. The study will focus on preventing escalation of substance use (e.g., alcohol and marijuana), trauma symptoms, and recidivism by using an intervention to target self-regulation and executive functioning.

Justice involved youth have higher rates of alcohol use and related consequences and higher rates of exposure to violence (Post Traumatic Stress Disorder) compared to their non-justice involved peers. Prior research has found aspects of self-regulation (emotion regulation, impulse control), stress, and craving to be important putative targets in reducing alcohol use. With high rates of recidivism and increased risk of long term problems associated with substance use, it is imperative to test interventions that can reach at risk youth and target both alcohol use and important psychological and neurocognitive self-regulation mechanisms.

This study tests whether the use of Mindfulness-Based Relapse Prevention (MBRP) for at risk young adults results in changes in important self-regulation mechanisms and improved alcohol use outcomes. Individuals assigned to the experimental group will receive interventions normally provided at a community clinic and eight 1.5-hour group sessions of MBRP. Sessions will occur once per week. Each session will target a specific theme such as being aware of personal triggers, maintaining present focus, allowing or letting things be, responding to emotional and physical experiences in skillful ways, and recognizing intrusive thoughts. Further, each session will incorporate a mindfulness meditation technique.

The central hypothesis will be tested through a focus on three specific aims: (1) Beta pilot testing and refining MBRP based on feedback from focus groups, (2) testing the efficacy of MBRP on substance use outcomes compared to an active control, and (3) assessing mechanisms of change for MBRP including self-regulation and neurocognitive facets such as working memory and inhibition.

Study Overview

Detailed Description

The long-term goal of this proposal is to improve alcohol use outcomes by targeting emotion regulation (ER), impulsivity (IMP), and executive functioning (EF) constructs among racially and ethnically diverse (primarily Hispanic and Black) at risk young adults. With a similar population, the investigators pilot tested a novel Mindfulness-Based Intervention (MBI), Mindfulness-Based Substance Abuse Treatment for Adolescents (MBRP) with with marginalized young adults. Findings from adolescent samples have found support for the intervention's effect on problem behaviors, decision making, and self-esteem. However, extent research in this area has not assessed substance use or self-regulation. In a sample of marginalized young adults receiving treatment at a residential treatment facility, MBRP was found to significantly decrease stress and substance use outcomes. In addition, only one study has investigated the effect of a MBI on neurocognitive functioning with justice-involved youth. Unfortunately, this was not a clinical intervention and did not assess EF as a mechanism of change. The current study proposes to recruit 70-80 young adults (aged 18-26) referred to one clinic in Los Angeles, CA. The study site has a wide range of referral sources ranging from self-referral to referrals from the justice system.

Some young adults are referred to treatment by schools in lieu of engaging law enforcement or in lieu of expulsion, with many being self-referred.

Participants will be randomly assigned to receive MBRP or attention control (CTL). Participants will engage in both self-report and task-based ER, IMP, and EF measures pre- and post-intervention. Participants will be followed for 3 months post-intervention to assess effects on alcohol use and behavioral health outcomes, and putative mechanisms of change.

The central hypothesis is that MBRP, compared to CTL, will prompt change in ER, IMP, and EF. Further, it is hypothesized that these changes will be associated with better alcohol use outcomes 3 months post-intervention. The rationale for using a MBI with marginalized youth is that prior research has shown significantly worse self-regulation compared to community youth, and MBRP is specifically designed to aid in regulating emotions, decision making, and attention control. The unique strengths of this proposal are its use of an MBI; focus on a disadvantaged population of diverse racial and ethnic groups; focus on putative targets essential to behavioral health outcomes; and use of multiple neurocognitive tasks addressing important self-regulation components. The study objective is to test following three aims:

Specific Aim 1: Determine feasibility and acceptability of abbreviated MBRP. An adapted MBRP protocol will be beta-tested with 15 transition age youth/young adults. Focus groups will be conducted to evaluate the feasibility and acceptability of an intervention focused on enhancing self-regulation, refine content based on feedback, and addressing issues that might affect the successful completion of pilot testing in Aim 2.

Specific Aim 2: Pilot test MBRP intervention on putative targets by randomly assigning young adults who screen for past-month alcohol use/problems to MBRP or CTL. Determine the effect of the program on secondary outcomes of interest and putative targets for ER, IMP, and EF.

Specific Aim 3: Assess MBRP mechanisms by exploring whether effects of the intervention on our substance use outcomes can be partially explained by changes in target mechanisms: ER, IMP, and EF.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Los Angeles, California, United States, 90089
        • University of Southern California, School of Social Work

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 26 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18 to 26 years old at baseline
  • English speaking
  • Be willing to provide follow-up information
  • Report past-month use of alcohol or drugs
  • Score 2 or higher on the PC-PTSD scale
  • Not currently receiving substance abuse treatment elsewhere
  • Not prisoners

Exclusion Criteria:

  • Does not speak English
  • Receiving treatment from some other facility for substance use.
  • Active psychosis symptoms

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: MBRP
The experimental group will receive treatment as usual plus eight Mindfulness based relapse prevention (MBRP) therapy sessions.
Individuals assigned to the experimental group will receive interventions normally provided at the clinic and eight 1.5-hour group sessions of MBRP. Each sessions will occur once per week and will target a specific theme such as being aware of personal triggers, maintaining present focus, allowing or letting things be, responding to emotional and physical experiences in skillful ways, and recognizing intrusive thoughts. Each session will incorporate a mindfulness meditation technique (e.g.,SOBER breathing space and "urge surfing"). Participants will receive materials (e.g., recordings) with which to perform practices and meditation during the intervention phase.
ACTIVE_COMPARATOR: Control (CTL)
The CTL group will receive treatment as usual plus information on the neurobiology of addiction and healthy behaviors.
Individuals assigned to the CTL group will receive interventions provided at the clinic and up to eight CTL sessions. The CTL group will receive information (reading) and videos once per week on health behaviors (e.g., exercise, eating) and the neurobiology of addiction. This approach will reduce the possibility that intervention effects are solely due to the experimental group's receiving extra attention. In contrast to the active intervention, sessions will be educational in nature, with no motivational, cognitive, or behavioral components

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Substance Use
Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Substance use will be measured using time line follow back approach for 15 different substances. We will ask about days of use and number of times used for each substance in the past month
Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Change in PTSD symptoms
Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Initial screening of PTSD symptoms will be assessed by the Primary Care PTSD Screen for DSM-5 (PC-PTSD-5). We will further assess PTSD symptoms using the PTSD Checklist for DSM-5 (PCL-5). The PCL-5 is a 20-item self-report measure that assesses the 20 Diagnostic and Statistical Manual of Mental Disorders (DSM-5) symptoms of PTSD.
Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Change in Depression
Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Depression will be measured with the Center for Epidemiologic Studies Depression Scale (CES-D). The CES-D includes 20 items instructing participants how often they have experienced a variety of symptoms in the past week, ranging from "rarely or none of the time" to "Most or all of the time." The scoring of positive items is reversed. Possible range of scores is zero to 60, with the higher scores indicating the presence of more symptomology.
Baseline, 1 month, 2 months, 3 months, 4 months, 5 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Executive Functioning
Time Frame: Baseline, 2 months post-baseline
Executive functioning will be assessed using the Sustained Attention to Response Task (SART). The SART is a computer-based go/no-go task that requires participants to withhold behavioral response to a single, infrequent target (often the digit 3) presented amongst a background of frequent non-targets (0-2, 4-9).
Baseline, 2 months post-baseline
Emotion Regulation
Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Emotion regulation will be assessed using the short-form Difficulties in Emotion Regulation Scale (DERS-18). The DERS-18 asks participants to indicate how often they respond to their emotions in a variety of ways. Response options range on a 5-point scale from 1 (almost never, 0-10%) to 5 (Almost always, 91-100%). To obtain a total score, three items are reverse-scored and responses are summed. Total scores range from 18 to 90. Higher scores indicate greater difficulty regulating emotions.
Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Impulsivity
Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
The SUPPS-P measures five components: Lack of premeditation, lack of perseverance, negative urgency, positive urgency, sensation seeking.
Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Delinquency
Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Delinquency will be assessed by self-reported offending.
Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Stress
Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Stress will be assessed using the Perceived Stress Scale (PSS). The PSS is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. The PSS consists of 10 items assessing perceived stress related to a variety of circumstances, with response options for each item existing on a 5-point scale ranging from 0 (never) to 4 (very often). Total PSS scores are obtained by reversing responses to the four positively stated items (items 4, 5, 7, & 8) and then summing across all scale items (range: 0 to 40). Higher PSS scores reflect higher levels of perceived stress.
Baseline, 1 month, 2 months, 3 months, 4 months, 5 months
Violence Perpetration
Time Frame: Baseline, 1 month, 2 months, 3 months, 4 months, 5 months

Violence perpetration will be assessed using the Illinois Bullying Scale. Point values are assigned to each response as follows: Never = 0, 1 or 2 times = 1, 3 or 4 times = 2, 5 or 6 times = 3, 7 or more times = 4. Summary scores for each subscale can be obtained by adding the responses for associated items:

  • Bully subscale: Items 1, 2, 8, 9, 14, 15, 16, 17, and 18
  • Victim subscale: Items 4, 5, 6, and 7
  • Fighting subscale: Items 3, 10, 11, 12, and 13

The Bully subscale score ranges from 0-36; the Victim subscale score ranges from 0-16; and the Fighting subscale score ranges from 0-20). Higher scores reflect higher levels of bullying, victimization, or fighting.

Baseline, 1 month, 2 months, 3 months, 4 months, 5 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 5, 2019

Primary Completion (ACTUAL)

June 30, 2020

Study Completion (ACTUAL)

June 30, 2020

Study Registration Dates

First Submitted

October 3, 2018

First Submitted That Met QC Criteria

November 9, 2019

First Posted (ACTUAL)

November 13, 2019

Study Record Updates

Last Update Posted (ACTUAL)

September 29, 2021

Last Update Submitted That Met QC Criteria

September 27, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Substance Use

Clinical Trials on Mindfulness Based Relapse Prevention

3
Subscribe